ABCG8 gene polymorphisms, plasma cholesterol concentrations, and risk of cardiovascular disease in familial hypercholesterolemia

被引:39
|
作者
Koeijvoets, Kristel C. M. C. [1 ]
van der Net, Jeroen B. [1 ,2 ]
Dallinga-Thie, Geesje M. [3 ]
Steyerberg, Ewout W. [2 ]
Mensink, Ronald P. [4 ]
Kastelein, John J. P. [3 ]
Sijbrands, Eric J. G. [1 ]
Plat, Jogchum [4 ]
机构
[1] Erasmus MC, Dept Internal Med, NL-3000 AC Rotterdam, Netherlands
[2] Erasmus MC, Dept Publ Hlth, NL-3000 AC Rotterdam, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands
[4] Maastricht Univ, Dept Human Biol, Maastricht, Netherlands
关键词
ABCG8; Polymorphism; Cardiovascular disease; Familial hypercholesterolemia; Plant sterols; CORONARY-HEART-DISEASE; SERUM PLANT STEROLS; NONCHOLESTEROL STEROLS; DIETARY-CHOLESTEROL; ARTERY-DISEASE; SITOSTEROLEMIA; ACCUMULATION; TRANSPORTERS; ASSOCIATION; METABOLISM;
D O I
10.1016/j.atherosclerosis.2008.09.018
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Elevated plasma plant sterol concentrations may be a risk factor of cardiovascular disease (CVD). Polymorphisms in the ABCG8 gene have been identified that contribute to the variation in plasma concentrations of plant sterols. However, data on the direct relationship of ABCG8 gene polymorphisms with CVD are lacking. Therefore, we examined associations between the D19H and T400K polymorphisms in the ABCG8 gene and CVD in a large cohort study of 2012 patients with heterozygous familial hypercholesterolemia (FH). A total of 244 individuals carried one or two alleles of the D19H variant and 568 individuals the T400K variant. During 94,809 person years, 648 (32.2%) individuals developed CVD of which coronary heart disease (CHD) was the most frequent cardiovascular event (N=553). In a Cox proportional hazard regression model adjusted for relevant cardiovascular risk factors, the D19H polymorphism was not associated with total CVD risk (p = 0.2), but there was evidence of an association with higher risk of CHD (RR 1.42, CI 1.04-1.95; p = 0.03). We observed no relationship between the T400K polymorphism and cardiovascular endpoints (p > 0.1). However, FH individuals carrying the risk genotype for both ABCG8 variants had an increased risk of CVD (RR 1.57, 95% CI 1.13-2.18; p = 0.01) and CHD (RR 1.72, 95% Cl 1.23-2.41; p = 0.002). In conclusion, our data suggest that genetic variation in the ABCG8 gene may influence the burden of atherosclerosis. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:453 / 458
页数:6
相关论文
共 50 条
  • [31] Serum bilirubin levels in familial hypercholesterolemia: a new risk marker for cardiovascular disease?
    Nolting, Pernette R. W. de Sauvage
    Kusters, D. Meeike
    Hutten, Barbara A.
    Kastelein, John J. P.
    JOURNAL OF LIPID RESEARCH, 2011, 52 (09) : 1755 - 1759
  • [32] The Role of Cumulative LDL Cholesterol in Cardiovascular Disease Development in Patients with Familial Hypercholesterolemia
    Korneva, Victoria
    Kuznetsova, Tatyana
    Julius, Ulrich
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (01):
  • [33] Association between lipoprotein(a) concentrations and atherosclerotic cardiovascular disease risk in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH
    Panagiotis Anagnostis
    Christos V. Rizos
    Ioannis Skoumas
    Loukianos Rallidis
    Konstantinos Tziomalos
    Emmanuel Skalidis
    Vasileios Kotsis
    Michalis Doumas
    Genovefa Kolovou
    George Sfikas
    Anastasia Garoufi
    Vaia Lambadiari
    Ioanna Dima
    Estela Kiouri
    Dimitrios Agapakis
    Evangelos Zacharis
    Christina Antza
    Vana Kolovou
    Charalambos Koumaras
    George Bantouvakis
    George Liamis
    Evangelos N. Liberopoulos
    Endocrine, 2022, 76 : 324 - 330
  • [34] Diet and Cardiovascular Disease Risk Among Individuals with Familial Hypercholesterolemia: Systematic Review and Meta-Analysis
    Barkas, Fotios
    Nomikos, Tzortzis
    Liberopoulos, Evangelos
    Panagiotakos, Demosthenes
    NUTRIENTS, 2020, 12 (08) : 1 - 22
  • [35] Association between lipoprotein(a) concentrations and atherosclerotic cardiovascular disease risk in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH
    Anagnostis, Panagiotis
    Rizos, Christos, V
    Skoumas, Ioannis
    Rallidis, Loukianos
    Tziomalos, Konstantinos
    Skalidis, Emmanuel
    Kotsis, Vasileios
    Doumas, Michalis
    Kolovou, Genovefa
    Sfikas, George
    Garoufi, Anastasia
    Lambadiari, Vaia
    Dima, Ioanna
    Kiouri, Estela
    Agapakis, Dimitrios
    Zacharis, Evangelos
    Antza, Christina
    Kolovou, Vana
    Koumaras, Charalambos
    Bantouvakis, George
    Liamis, George
    Liberopoulos, Evangelos N.
    ENDOCRINE, 2022, 76 (02) : 324 - 330
  • [36] TaqIB polymorphism in CETP gene: the influence on incidence of cardiovascular disease in statin-treated patients with familial hypercholesterolemia
    Mohrschladt, MF
    Beer, FVDSD
    Hofman, MK
    van der Krabben, M
    Westendorp, RGJ
    Smelt, AHM
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2005, 13 (07) : 877 - 882
  • [37] TaqIB polymorphism in CETP gene: the influence on incidence of cardiovascular disease in statin-treated patients with familial hypercholesterolemia
    Martina F Mohrschladt
    Femke van der Sman-de Beer
    Maaike K Hofman
    Marieke van der Krabben
    Rudi GJ Westendorp
    August HM Smelt
    European Journal of Human Genetics, 2005, 13 : 877 - 882
  • [38] Editorial Commentary: What Determines the Risk of Cardiovascular Disease in Familial Hypercholesterolemia?
    Brunham, Liam R.
    Mancini, G. B. John
    TRENDS IN CARDIOVASCULAR MEDICINE, 2021, 31 (04) : 216 - 217
  • [39] Difficulties in gauging atherosclerotic cardiovascular disease risk heterogeneity in familial hypercholesterolemia
    Mizuta, Marjorie H.
    Santos, Raul D.
    ATHEROSCLEROSIS, 2022, 354 : 57 - 59
  • [40] Risk factors for cardiovascular disease in heterozygous familial hypercholesterolemia: A systematic review and meta-analysis
    Akioyamen, Leo E.
    Genest, Jacques
    Chu, Anna
    Inibhunu, Happy
    Ko, Dennis T.
    Tu, Jack V.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2019, 13 (01) : 15 - 30